Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives
Lele Zhang, Jifa Zhang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 232, pp. 114176-114176
Closed Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition
Eikan Mishima, Toshitaka Nakamura, Jiashuo Zheng, et al.
Nature (2023) Vol. 619, Iss. 7968, pp. E9-E18
Open Access | Times Cited: 97
Ferroptosis mechanisms and regulations in cardiovascular diseases in the past, present, and future
Wenxi Fang, Saiyang Xie, Wei Deng
Cell Biology and Toxicology (2024) Vol. 40, Iss. 1
Open Access | Times Cited: 22
Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting Inhibitors To Combat Neurodegenerative Diseases
Hossein Mousavi, Mehdi Rimaz, Behzad Zeynizadeh
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 9, pp. 1828-1881
Closed Access | Times Cited: 8
Development of a Potent Nurr1 Agonist Tool for In Vivo Applications
Jan Vietor, Christian Gege, Tanja Stiller, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6391-6402
Open Access | Times Cited: 21
The role of ferroptosis in metabolic diseases
Ling Xie, Bin Fang, Chun Zhang
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research (2023) Vol. 1870, Iss. 6, pp. 119480-119480
Open Access | Times Cited: 18
Multi salt strategy based on curcumin pyrimidine derivatives prodrugs: Synthesis, biological activity, in vitro and in vivo imaging, and drug distribution research
Guangchang Lian, Ying Liu, Kaibo Hu, et al.
Dyes and Pigments (2023) Vol. 216, pp. 111310-111310
Closed Access | Times Cited: 11
Characteristics of anticancer activity of CBP/p300 inhibitors – Features of their classes, intracellular targets and future perspectives of their application in cancer treatment
Magdalena Strachowska, Agnieszka Robaszkiewicz
Pharmacology & Therapeutics (2024) Vol. 257, pp. 108636-108636
Open Access | Times Cited: 4
Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity
Christian Gege, Friedrich Hahn, Christina Wangen, et al.
ChemMedChem (2024) Vol. 19, Iss. 19
Open Access | Times Cited: 4
Inhibition of FSP1: A new strategy for the treatment of tumors (Review)
Qiangfang Dai, Xiaoli Wei, Jumei Zhao, et al.
Oncology Reports (2024) Vol. 52, Iss. 2
Open Access | Times Cited: 4
Environmental concentrations of TCEP and TDCIPP induce dysbiosis of gut microbiotal and metabolism in the honeybee (Apis mellifera L.)
Tao Cang, Weijie Gu, Yu Cheng Zhu, et al.
Journal of Hazardous Materials (2025), pp. 138039-138039
Closed Access
Enhanced tolerance of Clostridium tyrobutyricum to lignin-derived phenolic acids by overexpressing native reductases
Hailing Wei, Yuexin Wang, Yu Zeng, et al.
Journal of Biotechnology (2025)
Closed Access
Targeting vulnerability in tumor therapy: Dihydroorotate dehydrogenase
Fu Lin, Jiaxin Li, Lei Zhou, et al.
Life Sciences (2025), pp. 123612-123612
Closed Access
Discovery of piperine derivatives as inhibitors of human dihydroorotate dehydrogenase to induce ferroptosis in cancer cells
Jianfei Zhang, Li-Hong Hong, Shiying Fan, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107594-107594
Closed Access | Times Cited: 3
Discovery of potential natural dihydroorotate dehydrogenase inhibitors and their synergism with brequinar via integrated molecular docking, dynamic simulations and in vitro approach
Asmaa Khairy, Hala M. Hammoda, İsmail Çeli̇k, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety
Stefano Sainas, Marta Giorgis, Paola Circosta, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12701-12724
Open Access | Times Cited: 14
A Patent Review of Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors as Anticancer Agents and their Other Therapeutic Applications (1999-2022)
Pinky Gehlot, Vivek K. Vyas
Recent Patents on Anti-Cancer Drug Discovery (2023) Vol. 19, Iss. 3, pp. 280-297
Closed Access | Times Cited: 7
Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells
Tatsuro Watanabe, Yuta Yamamoto, Yuki Kurahashi, et al.
Blood Advances (2024) Vol. 8, Iss. 6, pp. 1345-1358
Open Access | Times Cited: 1
Radiosynthesis of [18F]Brequinar for in vivo PET Imaging of hDHODH for Potential Studies of Acute Myeloid Leukemia and Cancers
Vinay Kumar Banka, Stefano Sainas, Elena Martino, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 9, pp. 3147-3161
Open Access | Times Cited: 1
Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment
Ayenachew Bezawork‐Geleta, Diane Moujalled, David P. De Souza, et al.
Metabolites (2024) Vol. 14, Iss. 8, pp. 413-413
Open Access | Times Cited: 1
DHODH inhibitors sensitize cancer cells to ferroptosis via FSP1 inhibition
Eikan Mishima, Toshitaka Nakamura, Jiashuo Zheng, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 6
Tiratricol, a thyroid hormone metabolite, has potent inhibitory activity against human dihydroorotate dehydrogenase
Shuying Cao, Hui Ma, Zhaomin Xu, et al.
Chemical Biology & Drug Design (2023) Vol. 102, Iss. 1, pp. 1-13
Closed Access | Times Cited: 3
Identification of a dihydroorotate dehydrogenase inhibitor that inhibits cancer cell growth by proteomic profiling
Makoto Kawatani, Harumi Aono, Sayoko Hiranuma, et al.
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2023) Vol. 31, Iss. 6, pp. 833-844
Open Access | Times Cited: 3
Quinoline‐based thiazolyl‐hydrazones target cancer cells through autophagy inhibition
Vladimir Ćurčić, Mateusz Olszewski, Natalia Maciejewska, et al.
Archiv der Pharmazie (2023) Vol. 357, Iss. 2
Closed Access | Times Cited: 2
A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma
Chungen Li, Yue Zhou, Jing Xu, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114489-114489
Closed Access | Times Cited: 3
Discovery of Thiadiazoles as Human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors by Combined Structure‐Based Modelling Methods
Pinky Gehlot, Sunil Kumar, Vipin Kumar, et al.
ChemistrySelect (2024) Vol. 9, Iss. 10
Closed Access
Page 1 - Next Page

Scroll to top